Ceribell is a fast-growing medical device company (32% YoY growth, 4-quarter beat streak) with a strong moat, but it burns cash, quality scores 3.2/10 and the price is 8.4% above the analyst target.
Thesis pillars
- Strong Revenue Growth→Stable
- Cash Burn Weak Quality→Stable
- Price Above Analyst Target→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Feb 24, 2026
CeriBell, Inc. (CBLL) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Sell if holding. Engine safety override at $27.22: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality; Rich valuation.
CeriBell has developed the Ceribell System, an FDA-cleared point-of-care EEG platform paired with Clarity, an AI-powered algorithm for detecting seizures and, since a December 2025 clearance, delirium in critically ill patients. The company generated 88% gross margins in fiscal... Read more
Sell if holding. Engine safety override at $27.22: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality; Rich valuation. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Score 5.6/10, moderate confidence.
Passes 5/8 gates (positive momentum, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity and earnings proximity 5d<=7d. Suitability: aggressive.
Recent developments
updated 2026-10-29Recent Developments — CeriBell, Inc.
Latest news
- NEWS CeriBell CFO to Participate in Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum — fiscal.ai Oct 28, 2026 neutral
- NEWS CeriBell, Inc. Announces Third Quarter 2026 Financial Results Release Date — fiscal.ai Oct 20, 2026 neutral
- NEWS TD Cowen Maintains Buy on CeriBell, Raises Price Target to $33 — benzinga Oct 2, 2026 positive
- NEWS Ceribell Says FDA Cleared Brain Monitoring Software Update With No Age Restriction, Expects Rollout In 1H 2027 — benzinga Sep 30, 2026 positive
- NEWS Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday — benzinga Aug 18, 2026 neutral
Generated 2026-10-29T11:08:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCeribell System10-K Item 1A: 'We expect that revenue from sales of the Ceribell System will continue to account for almost all of our revenue for the foreseeable future.'
- HIGHGeographicUnited States sales100%10-K Item 1A: 'To date, all of our sales have been to customers in the United States.'
- HIGHSuppliertwo primary contract manufacturers in China10-K Item 1A: 'We rely on two primary contract manufacturers in China and maintain contractors in China who perform monitoring and quality inspection services.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -64.7%. Quality floor flags this regardless of sector context.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $27.22: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality; Rich valuation. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Prior stop was $25.31. Score 5.6/10, moderate confidence.
Analyst target $24.86 reached (−8.7% from $27.22); no take-profit level is published. Prior stop was $25.31. Stop-loss: $25.31.
Concentration risk — Product: Ceribell System; Concentration risk — Geographic: United States sales (100.0%); Target reached (-8.7% upside).
CeriBell, Inc. trades at a P/E of N/A (forward -16.9). TrendMatrix value score: 3.7/10. Verdict: Sell.
14 analysts cover CBLL with a consensus score of 4.4/5. Average price target: $29.
What does CeriBell, Inc. do?CeriBell has developed the Ceribell System, an FDA-cleared point-of-care EEG platform paired with Clarity, an...
CeriBell has developed the Ceribell System, an FDA-cleared point-of-care EEG platform paired with Clarity, an AI-powered algorithm for detecting seizures and, since a December 2025 clearance, delirium in critically ill patients. The company generated 88% gross margins in fiscal 2025 from a recurring revenue model combining disposable Wearable sales and Clarity/portal subscription fees, has deployed to more than 600 U.S. hospitals, and to date has sold exclusively to customers in the United States. CeriBell relies on two primary contract manufacturers in China for assembly of its disposable Wea